Vaccentis is pleased to announce the signing of a letter of intent for a strategic partnership with TrueMed Therapeutics.
We believe that this collaboration will provide significant support for the continued development of Vaccentis's individualized tumour vaccine, VCC-001, as well as its broader pipeline!
